

#### DESCRIPTION

**Source** Chinese Hamster Ovary cell line, CHO-derived  
Ala279-Ser390  
Accession # NP\_001075318

**N-terminal Sequence Analysis** Ala279

**Structure / Form** Disulfide-linked homodimer

**Predicted Molecular Mass** 13 kDa

#### SPECIFICATIONS

**SDS-PAGE** 11-13 kDa, reducing conditions

**Activity** Measured by its ability to inhibit the IL-4-dependent proliferation of HT-2 mouse T cells. Tsang, M. *et al.* (1995) *Cytokine* 7:389. The ED<sub>50</sub> for this effect is 0.04-0.2 ng/mL.

**Endotoxin Level** <0.10 EU per 1 µg of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE with silver staining.

**Formulation** Lyophilized from a 0.2 µm filtered solution in HCl. See Certificate of Analysis for details.

#### PREPARATION AND STORAGE

**Reconstitution** Reconstitute at 100 µg/mL in 4 mM HCl.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

#### BACKGROUND

TGF-β1 (transforming growth factor beta 1) is one of three closely related mammalian members of the large TGF-β superfamily that share a characteristic cystine knot structure (1-7). TGF-β1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation, and epithelial-mesenchymal transition (1-4). Each TGF-β isoform has some non-redundant functions; for TGF-β1, mice with targeted deletion show defects in hematopoiesis and endothelial differentiation and die of overwhelming inflammation (2). Equine TGF-β1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-β1 (8, 9). Disulfide-linked homodimers of LAP and TGF-β1 remain non-covalently associated after secretion, forming the small latent TGF-β1 complex (8-10). Covalent linkage of LAP to one of three latent TGF-β binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-β is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature equine TGF-β1 shares 98% aa identity with mouse, rat, and human TGF-β1, 99% aa identity with pig and dog TGF-β1, and 88% aa identity with cow TGF-β1. It demonstrates cross-species activity (1). TGF-β1 signaling begins with high-affinity binding to a type II Ser/Thr kinase receptor termed TGF-β RII. This receptor then phosphorylates and activates a second Ser/Thr kinase receptor, TGF-β RI/ALK-5, or alternatively, ALK-1. This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors TGF-β RIII/Betaglycan and Endoglin/CD105, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-β in different contexts (11).

#### References:

1. Derynck, R. and K. Miyazono (2008) "TGF-β and the TGF-β family" in *The TGF-β Family*. Cold Spring Harbor Laboratory Press.
2. Dunker, N. and K. Kriegstein (2000) *Eur. J. Biochem.* **267**:6982.
3. Wahl, S.M. (2006) *Immunol. Rev.* **213**:213.
4. Chang, H. *et al.* (2002) *Endocr. Rev.* **23**:787.
5. Lin, J.S. *et al.* (2006) *Reproduction* **132**:179.
6. Hinck, A.P. *et al.* (1996) *Biochemistry* **35**:8517.
7. Mittl, P.R.E. *et al.* (1996) *Protein Sci.* **5**:1261.
8. Derynck, R. *et al.* (1985) *Nature* **316**:701.
9. Miyazono, K. *et al.* (1988) *J. Biol. Chem.* **263**:6407.
10. Oklu, R. and R. Hesketh (2000) *Biochem. J.* **352**:601.
11. de Caestecker, M. *et al.* (2004) *Cytokine Growth Factor Rev.* **15**:1.
12. Zuniga, J.E. *et al.* (2005) *J. Mol. Biol.* **354**:1052.